Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (ABCL) is a leader in antibody discovery, combining microfluidics and advanced data science to accelerate therapeutic development. This page consolidates all official announcements and analysis-worthy updates about the company's progress in biopharmaceutical innovation.
Investors and industry observers will find timely updates on clinical milestones, financial performance, and strategic collaborations. Our curated feed includes earnings reports, partnership announcements with pharmaceutical entities, regulatory developments, and technological advancements in ABCL's antibody screening platform.
The resource prioritizes clarity and accessibility, offering both high-level summaries for casual observers and detailed technical updates for research-focused professionals. Content types include quarterly financial disclosures, intellectual property updates, executive leadership changes, and progress reports on therapeutic candidates in development.
Bookmark this page for streamlined tracking of ABCL's contributions to oncology, infectious disease treatment, and autoimmune disorder research. Check regularly for verified updates on how the company's proprietary discovery platform continues reshaping biotherapeutic development timelines.
AbCellera (NASDAQ: ABCL) announced a modified purchase agreement with Eli Lilly to supply 150,000 doses of bebtelovimab to the U.S. government for approximately $275 million. This supply is set to meet current demand through late August 2022, with deliveries starting immediately. An additional option for 350,000 doses is available until September 14, 2022. Bebtelovimab retains neutralization efficacy against prevalent Omicron variants in the U.S. AbCellera's efforts led to the development of significant COVID-19 treatments, including bamlanivimab and bebtelovimab, showcasing its capabilities in pandemic response.
AbCellera (Nasdaq: ABCL) reported total revenues of $317 million for Q1 2022, up from $203 million a year earlier, with net earnings of $168.6 million (or $0.59 per basic share) compared to $117.2 million (or $0.43 per basic share) in Q1 2021. The company initiated six new drug discovery programs, bringing the cumulative total to 84, a 56% increase from the previous year. R&D expenses rose to $26.4 million, reflecting increased investments in their platform. The company ended the quarter with $786.1 million in cash and equivalents.
AbCellera (NASDAQ: ABCL) has announced an expansion of its collaboration with Empirico Inc., increasing their targets from five to seven. The partnership utilizes Empirico's Precision Insights Platform for drug target discovery and AbCellera's technology for identifying lead candidate antibodies. The companies successfully identified a lead candidate in under 12 months. The new agreement allows AbCellera to co-develop therapeutic programs, maintaining up to a 50% ownership stake in the resulting antibodies, although financial terms were not disclosed.
AbCellera (Nasdaq: ABCL) has announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, in Toronto, Canada. The presentation will commence at 6:30 a.m. PT (9:30 a.m. ET). A live audio webcast will be available on AbCellera's Investor Relations website, with a replay accessible post-event. AbCellera specializes in leveraging immune system analysis to discover antibodies that can be developed into therapeutic drugs, collaborating with various drug developers to enhance drug development efficiency.
AbCellera (NASDAQ: ABCL) is set to announce its first quarter 2022 financial results on May 10, 2022, at 2:00 PM PT. An earnings conference call will follow the announcement, with a live audio webcast available on AbCellera's Investor Relations website. The company specializes in antibody discovery, collaborating with drug developers to optimize drug development processes. More details will be disclosed during the earnings call.
AbCellera (Nasdaq: ABCL) unveiled data on its innovative T cell engager platform at the AACR 2022 Annual Meeting. The research showcases a diverse range of CD3-binding antibodies for developing bispecific T cell engagers aimed at enhancing cancer therapies. Bo Barnhart, VP of Translational Research, emphasized the potential of these new antibodies to boost the efficacy of oncology treatments. The platform combines rapid screening capabilities with favorable developability properties, reducing engineering risks and enhancing the probability of successful cancer drug development.
AbCellera (Nasdaq: ABCL) reported a total revenue of $375 million for 2021, a 61% increase from $233 million in 2020. The company ended the year with liquidity exceeding $720 million. Key achievements included 26 new program starts, totaling 78 cumulative starts. Net earnings rose to $153 million ($0.56 per share), up from $119 million ($0.53 per share) in 2020. R&D expenses increased to $62 million, reflecting investment in the company's platform. AbCellera also expanded its partner network significantly, increasing programs under contract to 156.
AbCellera (Nasdaq: ABCL) announced its participation in the Truist Securities AI Symposium on March 1, 2022, at 8:20 a.m. Pacific Time. The panel, titled “Integrated Platforms for AI-based Drug Discovery,” will feature executives from the Company discussing groundbreaking advancements in drug development. Interested parties can access a live audio webcast through AbCellera's Investor Relations website, with a replay available afterwards. AbCellera specializes in antibody discovery, partnering with various drug developers to expedite the development process for new treatments.
AbCellera (Nasdaq: ABCL) will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 12:40 p.m. PT. Investors and interested parties can access the live audio webcast on AbCellera's Investor Relations website, with a replay available afterward. AbCellera is a tech company specializing in analyzing immune systems to discover antibodies for drug development, partnering with pharmaceutical and biotechnology firms to streamline processes and address challenges in drug development.
AbCellera (Nasdaq: ABCL) has received Emergency Use Authorization (EUA) from the U.S. FDA for bebtelovimab (LY-CoV1404), its antibody treatment for mild-to-moderate COVID-19 in high-risk patients. Bebtelovimab effectively neutralizes the Omicron variant, including BA.2, demonstrating broad efficacy against circulating SARS-CoV-2 variants. The authorized dosage is 175 mg as an intravenous injection. Additionally, Lilly has contracted to supply up to 600,000 doses to the U.S. government by March 31, 2022, and an option for 500,000 more by July 31, 2022.
